Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) studyPierre‐François Laterre, Jean-Baptiste Lascarrou, Gernot Marx et al.|Critical Care|2018Cited by 134
Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) StudyAlexa Hollinger, Matthieu Legrand, Xavier Wittebole et al.|Kidney International Reports|2018Cited by 108
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Bruno François et al.|Critical Care|2022Cited by 93
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre‐François Laterre, Anne-Aurore Duchambon, Peter Pickkers et al.|Intensive Care Medicine|2021Cited by 92
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Hasan S. Jafri et al.|The Lancet Infectious Diseases|2021Cited by 88